AGIO250117C22500
- 0.00
- 0.000.00%
Agios Pharmaceuticals Newsroom
BofA Securities Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Announces Target Price $55
Agios Pharmaceuticals Price Target Lowered to $55 From $60 at BofA
Express News | Agios Pharmaceuticals - to Discontinue Pyrukynd if Hepatic Injury Due to Pyrukynd Is Suspected
Express News | Agios Pharmaceuticals - Uspi Sections Updated to Include Liver Injury Information
Express News | Agios Pharmaceuticals - FDA Approves Update to Uspi for Pyrukynd for Hemolytic Anemia
How to Navigate the Stock and Bond Markets in 2025 -- Journal Report
Agios to Present at the 43rd Annual J.P. Morgan Healthcare Conference on January 15, 2025
The Best U.S. Value Stocks by Quant: AGIO, DLX, PPC
TD Cowen Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating
Express News | Cantor Fitzgerald Reiterates Overweight on Agios Pharmaceuticalsto Overweight
The European Commission Has Adopted A Positive Decision For The Designation Of Agios Pharmaceuticals' Mitapivat As An Orphan Medicinal Product For Sickle Cell Disease
European Commission Adopts Positive Decision for Orphan Medicinal Product Designation of Agios' Mitapivat in Sickle Cell Disease
Tesla, Micron, Broadcom, MARA Holdings And Other Big Stocks Moving Higher On Monday
Here's Why Agios Stock Plummeted More Than 20% on Monday
Scotiabank Maintains Agios Pharmaceuticals(AGIO.US) With Buy Rating, Maintains Target Price $75
RBC Raises Price Target on Agios Pharmaceuticals to $57 From $55, Keeps Outperform Rating
Small U.S. Stocks Decrease; Agios Pharmaceuticals Posts Biggest Loss
Agios Pharmaceuticals Down Nearly 22%, on Pace for Record Percent Decrease -- Data Talk
Agios Pharmaceuticals Is Maintained at Sector Outperform by Scotiabank
Agios Pharmaceuticals Analyst Ratings